A severe case of bevacizumab-induced thrombotic microangiopathy

Bektas M., Samanci N., Cokgezer S., Keskin D., Demirelli F. H.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.25, no.7, pp.1754-1757, 2019 (SCI-Expanded) identifier identifier identifier


Bevacizumab is a human monoclonal antibody against VEGF. Many adverse reactions about bevacizumab are identified including venous and arterial thromboembolism, nausea, fatigue, alopecia, proteinuria, gastrointestinal system (GIS) perforation, exfoliative dermatitis, and peripheral edema and thrombocytopenia. In this paper, we report a case of bevacizumab-induced dose-dependent, toxicity-mediated drug-induced thrombotic microangiopathy.